SALT LAKE CITY, UT--(Marketwire - December 15, 2009) -
Paradigm Medical Industries, Inc.
) announced today that it introduced two new products at the
annual American Academy of Ophthalmology Meeting in San Francisco from
October 24-27, 2009. The new products consisted of the Paravue 300, a
corneal topographer, and the Surveyor 500, a fully capable corneal
topographer with a Scheimpflug technology rotating camera for the
measurement of interior ocular structures in the anterior segment.
These are the first two products Paradigm is introducing from its Italian
partner, Costruzione Strumenti Oftalmici (C.S.O.), with additional products
scheduled for 2010. The Paravue 300 and Surveyor 500 fill a gap created by
an earlier decision to discontinue manufacturing the CT 200 (corneal
topographer), which was outdated.
"The AAO attendees response to the Paravue 300 and Surveyor 500 was very
impressive and will serve as a springboard for Paradigm to continue to
develop, locate and introduce new and innovative products to the ophthalmic
marketplace," said Stephen Davis, Paradigm President and CEO.
Paradigm Medical also announced the relocation of its corporate office to
4273 South 590 West, Salt Lake City, Utah 84123. All phone numbers will
remain the same. "This move will provide Paradigm with a more suitable
facility that meets its current manufacturing and operational needs and
reduces its overhead cost," said Mr. Davis.
About Paradigm Medical Industries, Inc.
Headquartered in Salt Lake City, Utah, Paradigm Medical Industries, Inc. is
a medical device company that develops, manufactures and distributes
ophthalmic diagnostic instruments and related products for early glaucoma
detection and other eye disorders. Paradigm has the only patented
technology utilizing photon laser for cataract removal. The Company is
poised to capture a niche market within the glaucoma and ultrasound
microscopy fields. Paradigm Medical Industries markets its products to
ophthalmologists, optometrists, universities, and clinics throughout the
United States, as well as internationally.
This press release contains statements that, if not verifiable historic
fact, may be viewed as forward-looking statements that could predict future
events and outcomes with respect to Paradigm and its business. The
predictions embodied in these statements will involve risk and
uncertainties and, accordingly, actual results may differ significantly
from the results discussed or implied in such forward-looking statements.
For more information, please visit: www.paradigm-medical.com